<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.ajmc.com/view/inhaled-treprostinil-improves-fvc-in-ipf-phase-3-trial-steven-d-nathan-md</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a784d1b6bdcf2bf61cf7d4624ebf5674f1eae713-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Inhaled Treprostinil Improves FVC in IPF Phase 3 Trial: Steven D. Nathan, MD]]></video:title><video:description><![CDATA[Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393501704112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bispecific-antibodies-are-reshaping-multiple-myeloma-care-prerna-mewawalla-md</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e85211dad79c04188cf0a9eea038aae7be4cdc90-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Bispecific Antibodies Are Reshaping Multiple Myeloma Care: Prerna Mewawalla, MD]]></video:title><video:description><![CDATA[Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393575383112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pediatric-care-deserts-and-emergency-room-reliance-chris-johnson-mba</loc><video:video><video:publication_date>2026-04-24</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/186b5049a053c4b5a8ecc3e8da7e7d9a66266d1b-1472x808.png</video:thumbnail_loc><video:title><![CDATA[Closing the Pediatric Care Gap Through Primary Care Reimbursement Reform: Chris Johnson, MBA]]></video:title><video:description><![CDATA[Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393733160112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/specialty-pharmacy-s-critical-role-as-advanced-therapies-move-into-the-community-fran-gregory-pharmd-mba</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1232a9adc9f3195dd0b6bbecf0f4a681f9e13033-2771x1439.png</video:thumbnail_loc><video:title><![CDATA[Specialty Pharmacy's Critical Role as Advanced Therapies Move Into the Community: Fran Gregory, PharmD, MBA]]></video:title><video:description><![CDATA[Fran Gregory, PharmD, MBA, explains why community providers can't go it alone—and how specialty pharmacy is stepping in to carry the load. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393735939112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/access-timing-workflow-challenges-shape-biomarker-testing-in-nsclc-parth-desai-mbbs-md</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5bc49e7606f10be50c9a40477ce24dfe12022dec-1245x696.png</video:thumbnail_loc><video:title><![CDATA[Access, Timing, Workflow Challenges Shape Biomarker Testing in NSCLC: Parth Desai, MBBS, MD]]></video:title><video:description><![CDATA[Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393501013112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cemdisiran-safe-to-take-has-low-treatment-burden-in-gmg-tuan-vu-md</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88b997b0a027b4504d493eb7acbb7726e760e48c-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Cemdisiran Safe to Take, Has Low Treatment Burden in gMG: Tuan Vu, MD]]></video:title><video:description><![CDATA[Cemdisiran offers lower treatment burden for patients living with generalized myasthenia gravis, only needing to be taken every 3 months.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393306050112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/amcp-2026-highlights-managed-care-trends-in-oncology-policy-and-innovation</loc><video:video><video:publication_date>2026-04-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cfad761b066e64488506ddaf32e2c91a14da7d13-352x143.png</video:thumbnail_loc><video:title><![CDATA[AMCP 2026 Highlights: Managed Care Trends in Oncology, Policy, and Innovation]]></video:title><video:description><![CDATA[AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393650329112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/expanding-the-toolkit-non-statin-therapies-broader-populations-and-closing-the-treatment-gap</loc><video:video><video:publication_date>2026-04-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Expanding the Toolkit: Non-Statin Therapies, Broader Populations, and Closing the Treatment Gap]]></video:title><video:description><![CDATA[For the first time, the 2026 ACC/AHA guideline provides strong, evidence-based recommendations for patients who cannot tolerate statins—a group historically underserved by prior guidance. Outcome data now support bempedoic acid (from the CLEAR trial), PCSK9 monoclonal antibodies, ezetimibe, and inclisiran as viable alternatives. Rather than defaulting to high-intensity statin doses, clinicians can consider combination strategies such as a moderate-intensity statin paired with ezetimibe—a pairing shown in the RACING trial to match the cardiovascular event reduction of high-intensity monotherapy while improving tolerability and LDL goal achievement. The "rule of sixes"—where doubling a statin dose yields only an additional 6% LDL reduction versus 18% from adding ezetimibe—further reinforces early combination thinking.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573046112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/starting-sooner-targeting-lower-how-updated-acc-aha-guidelines-redefine-lipid-lowering-strategy</loc><video:video><video:publication_date>2026-04-22</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cf9ce71c1f1cd31d9003a406535286464df9db3c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Starting Sooner, Targeting Lower: How Updated ACC/AHA Guidelines Redefine Lipid-Lowering Strategy]]></video:title><video:description><![CDATA[The 2026 update to the ACC/AHA guideline for dyslipidemia management represents a meaningful shift in how and when clinicians should begin lipid-lowering therapy, Erin D. Michos, MD, MHS, professor of medicine, director of Women's Cardiovascular Health and associate director of Preventive Cardiology in the Division of Cardiology at Johns Hopkins University School of Medicine, explains. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393573566112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/decentralized-trials-hold-promise-but-cost-infrastructure-challenges-remain-arturo-loaiza-bonilla-md</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2995dc687e6a306d6a5621623938143579d32635-1233x696.png</video:thumbnail_loc><video:title><![CDATA[Decentralized Trials Hold Promise, but Cost, Infrastructure Challenges Remain: Arturo Loaiza-Bonilla, MD]]></video:title><video:description><![CDATA[Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393484550112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nimble-trial-shows-efficacy-of-cemdisiran-in-gmg-tuan-vu-md</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88b997b0a027b4504d493eb7acbb7726e760e48c-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[NIMBLE Trial Shows Efficacy of Cemdisiran in gMG: Tuan Vu, MD]]></video:title><video:description><![CDATA[Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393300464112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/guideline-updates-reflect-growing-role-of-immunotherapy-in-cscc</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Guideline Updates Reflect Growing Role of Immunotherapy in CSCC]]></video:title><video:description><![CDATA[Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant settings and offering durable disease control in high-risk patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139583112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unmet-needs-and-key-takeaways-for-community-oncologists</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unmet Needs and Key Takeaways for Community Oncologists]]></video:title><video:description><![CDATA[Chemotherapy sequencing in the ARPI era and the role of radiopharmaceuticals versus docetaxel remain unsettled, while genetics and PSMA-PET emerge as essential themes for community oncologists.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392159179112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-future-of-psoriasis-management-integration-innovation-and-holistic-care</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[The Future of Psoriasis Management: Integration, Innovation, and Holistic Care]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, offers a forward-looking synthesis of how psoriasis care has evolved toward holistic, personalized management—and where advances in oral therapies, biomarker-guided selection, and equitable access will define the next era of treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392168801112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rethinking-when-to-start-long-acting-hiv-therapy</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[Rethinking When to Start Long-Acting HIV Therapy]]></video:title><video:description><![CDATA[Real-world data suggest long-acting injectables may help achieve—not just maintain—viral suppression.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392179222112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/psma-pet-and-the-evolving-imaging-landscape-in-prostate-cancer</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[PSMA PET and the Evolving Imaging Landscape in Prostate Cancer]]></video:title><video:description><![CDATA[Radium-223 retains a role in osteoblastic bone-only disease, while PSMA PET has become indispensable across staging, recurrence detection, and patient selection for radioligand therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392160162112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/selecting-patients-for-immunotherapy-in-cscc-key-considerations</loc><video:video><video:publication_date>2026-04-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Selecting Patients for Immunotherapy in CSCC: Key Considerations]]></video:title><video:description><![CDATA[Clinicians should consider systemic immunotherapy earlier in CSCC—especially in moderate- to high-risk cases—using a multidisciplinary, patient-centered approach to guide treatment decisions. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139094112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/addressing-family-caregiver-burden-in-breast-cancer-care-alyson-moadel-robblee-phd</loc><video:video><video:publication_date>2026-04-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2843beae38cd20692ca6651f45643728046767eb-1974x1164.png</video:thumbnail_loc><video:title><![CDATA[Addressing Family Caregiver Burden in Breast Cancer Care: Alyson Moadel-Robblee, PhD]]></video:title><video:description><![CDATA[Alyson Moadel-Robblee, PhD, outlines how the BOLD Program proactively supports cancer caregivers through community-based care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392153050112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/emerging-therapies-in-multiple-myeloma-shift-focus-toward-cure-asya-nina-varshavsky-yanovsky-md-phd</loc><video:video><video:publication_date>2026-04-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ede8e9efb967505bdf9139ee9480fbcc68fb3b0f-1233x694.png</video:thumbnail_loc><video:title><![CDATA[Emerging Therapies in Multiple Myeloma Shift Focus Toward Cure: Asya Nina Varshavsky-Yanovsky, MD, PhD]]></video:title><video:description><![CDATA[New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393319162112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/managing-infection-risks-in-bcma-bispecific-antibody-therapy-ajay-k-nooka-md-mph</loc><video:video><video:publication_date>2026-04-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a926661cf4d2e312bf314be11f52e147665b8c1b-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Managing Infection Risks in BCMA Bispecific Antibody Therapy: Ajay K. Nooka, MD, MPH]]></video:title><video:description><![CDATA[Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393235656112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/co-pay-models-and-afps-shift-costs-but-raise-access-concerns-patty-taddei-allen-pharmd-mba</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/028cc559f8b52e0e8f9b8ffbb5aaa29d137c64d1-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Co-Pay Models and AFPs Shift Costs but Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA]]></video:title><video:description><![CDATA[Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393310589112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/alternatives-to-pain-act-raises-access-and-market-stability-concerns-adam-colborn-jd</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6afe35939c56736b957cc0ee4417ecc82fca2997-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Alternatives to PAIN Act Raises Access and Market Stability Concerns: Adam Colborn, JD]]></video:title><video:description><![CDATA[At AMCP 2026, Adam Colborn, JD, warns the Alternatives to PAIN Act may expand access but risk destabilizing Medicare Part D and limiting plan participation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393310382112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/amplify-redefines-cll-care-adam-kittai-md</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/92df45a64e69e0d648faa53a3bee6e91f41ec87e-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[AMPLIFY Redefines CLL Care: Adam Kittai, MD ]]></video:title><video:description><![CDATA[Time-limited acalabrutinib plus venetoclax improves outcomes vs chemoimmunotherapy, offering the first FDA-approved all-oral fixed-duration CLL option, explains Adam Kittai, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393315984112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/oncology-trends-and-testing-gaps-shape-precision-care-delivery-abby-kim-pharmd</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0f48ed64dd392a86a4143a65c3f32e8d5c40c560-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Oncology Trends and Testing Gaps Shape Precision Care Delivery: Abby Kim, PharmD]]></video:title><video:description><![CDATA[Abby Kim, PharmD, delves into oncology trends, biomarker testing gaps, and evolving clinical pathways shaping precision care and treatment decisions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId= 6393298960112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/glp-1-coverage-gaps-and-real-world-evidence-shape-access-trends-ben-urick-pharmd-phd</loc><video:video><video:publication_date>2026-04-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/22b57474ca6fba3274b19ef8cf9f870bd0eec323-1200x640.png</video:thumbnail_loc><video:title><![CDATA[GLP-1 Coverage Gaps and Real-World Evidence Shape Access Trends: Ben Urick, PharmD, PhD]]></video:title><video:description><![CDATA[Ben Urick, PharmD, PhD, examines GLP-1 coverage gaps and real-world evidence challenges shaping payer decisions and obesity treatment access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393296758112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/staging-ctdna-and-the-art-of-personalizing-metastatic-breast-cancer-therapy-hayley-knollman-md</loc><video:video><video:publication_date>2026-04-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0e2fd4d273db1cf4167694eec2b41d8c288d35f8-1171x654.png</video:thumbnail_loc><video:title><![CDATA[Staging, ctDNA, and the Art of Personalizing Metastatic Breast Cancer Therapy: Hayley Knollman, MD]]></video:title><video:description><![CDATA[Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393240947112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/precision-medicine-gaps-persist-amid-evidence-and-access-challenges-daryl-pritchard-phd</loc><video:video><video:publication_date>2026-04-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c9558e70050b56ccfdbd0f3ba8c2eeb221ff7c34-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Precision Medicine Gaps Persist Amid Evidence and Access Challenges: Daryl Pritchard, PhD]]></video:title><video:description><![CDATA[At AMCP 2026, Daryl Pritchard, PhD, highlighted fragmentation, evidence gaps, and decision support needs limiting precision medicine adoption and outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393173067112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-acting-hiv-therapies-improve-adherence-and-access-options-kelsea-aragon-pharmd</loc><video:video><video:publication_date>2026-04-16</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5d4abc57d5fae08efcf4492618d38bae79c60b94-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Long-Acting HIV Therapies Improve Adherence and Access Options: Kelsea Aragon, PharmD]]></video:title><video:description><![CDATA[Kelsea Aragon, PharmD, highlights the role of long-acting HIV therapies like lenacapavir and cabotegravir in improving adherence, flexibility, and prevention access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393172977112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rising-specialty-drug-costs-and-co-pay-models-raise-access-concerns-patty-taddei-allen-pharmd-mba</loc><video:video><video:publication_date>2026-04-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/028cc559f8b52e0e8f9b8ffbb5aaa29d137c64d1-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rising Specialty Drug Costs and Co-Pay Models Raise Access Concerns: Patty Taddei-Allen, PharmD, MBA]]></video:title><video:description><![CDATA[Patty Taddei-Allen, PharmD, MBA, warns that co-pay accumulators and maximizers may lower plan costs but increase patient burden and disrupt medication adherence.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393172574112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/amcp-2026-policy-push-targets-value-based-care-access-expansion-adam-colborn-jd</loc><video:video><video:publication_date>2026-04-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d8c3d4252bb4628c9b1ab6f743e15d8fc399ecf1-1200x640.png</video:thumbnail_loc><video:title><![CDATA[AMCP 2026 Policy Push Targets Value-Based Care Access Expansion: Adam Colborn, JD]]></video:title><video:description><![CDATA[Adam Colburn, JD, highlights 3 federal bills to expand value-based care, digital therapeutics, and pharmacist reimbursement across Medicare and Medicaid.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393173175112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/talking-to-children-about-breast-cancer-alyson-moadel-robblee-phd</loc><video:video><video:publication_date>2026-04-15</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2843beae38cd20692ca6651f45643728046767eb-1974x1164.png</video:thumbnail_loc><video:title><![CDATA[Talking to Children About Breast Cancer: Alyson Moadel-Robblee, PhD]]></video:title><video:description><![CDATA[Alyson Moadel-Robblee, PhD, provides a closer look at how families, especially children, experience a breast cancer diagnosis and why transparency and inclusion are key to healthy coping.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392147658112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/breaking-down-trump-s-renewed-push-on-price-transparency-john-barkett-mba</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d8dd1323e8cb671af7f493a4d9b25ba7ddcefc5c-2614x1263.png</video:thumbnail_loc><video:title><![CDATA[Breaking Down Trump's Renewed Push on Price Transparency: John Barkett, MBA]]></video:title><video:description><![CDATA[John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393105343112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/shawn-davis-md-on-access-coverage-and-the-future-of-obesity-therapy</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/874fce1d80d5a7f0aa6c50f9e3dcee1701d3b017-2934x1624.png</video:thumbnail_loc><video:title><![CDATA[Shawn Davis, MD, on Access, Coverage, and the Future of Obesity Therapy]]></video:title><video:description><![CDATA[Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392687285112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/building-trust-not-just-enrollment-amy-leader-drph-mph-on-community-trial-success</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7eb3b2fe08cc36a0d42ed50be6c15f2e6876cdea-1268x717.png</video:thumbnail_loc><video:title><![CDATA[Building Trust, Not Just Enrollment: Amy Leader, DrPH, MPH, on Community Trial Success ]]></video:title><video:description><![CDATA[Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6393031118112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/radium-223-in-the-modern-era-patient-selection-and-sequencing</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Radium-223 in the Modern Era: Patient Selection and Sequencing]]></video:title><video:description><![CDATA[Bone-only, osteoblastic disease and the absence of prior ARPI exposure define the optimal radium-223 candidate, while sequencing relative to lutetium-177 PSMA-617 remains an active area of investigation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392158988112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/understanding-discontinuation-and-biologic-sequencing-in-psoriasis</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[Understanding Discontinuation and Biologic Sequencing in Psoriasis]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, examines the non-clinical reasons driving real-world treatment discontinuation and explains how clinicians use primary versus secondary loss of efficacy to guide biologic sequencing decisions across IL-23 and IL-17 classes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392167444112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-term-persistence-with-tildrakizumab-in-real-world-practice</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[Long-Term Persistence With Tildrakizumab in Real-World Practice]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, reviews real-world persistence data for tildrakizumab, discussing the interplay of clinical efficacy, insurance coverage, and buy-and-bill reimbursement in driving long-term treatment durability—particularly among Medicare and Medicaid patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392166965112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-rise-of-2-drug-strategies-tailoring-hiv-treatment-for-an-aging-population</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[The Rise of 2-Drug Strategies: Tailoring HIV Treatment for an Aging Population]]></video:title><video:description><![CDATA[DOR/ISL exemplifies how 2-drug regimens could meet the complex needs of an aging HIV population.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392179221112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sequencing-by-prior-exposure-how-the-mcrpc-treatment-map-has-changed</loc><video:video><video:publication_date>2026-04-14</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Sequencing by Prior Exposure: How the mCRPC Treatment Map Has Changed]]></video:title><video:description><![CDATA[The mCRPC section's reorganization by prior treatment exposure reflects how ARPI and docetaxel use in the hormone-sensitive setting now defines—and constrains—options in the castration-resistant phase.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392159972112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/psychological-aspects-of-alopecia-areata-needs-focus-in-the-future-maria-hordinsky-md</loc><video:video><video:publication_date>2026-04-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/85b9d1499db4b92c856b5d84b30195913ce55650-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Psychological Aspects of Alopecia Areata Need Focus in the Future: Maria Hordinsky, MD]]></video:title><video:description><![CDATA[Psychological effects of alopecia areata should be looked into in the future for patients who live with the condition.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392874140112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nurse-navigation-reflex-testing-key-to-closing-molecular-testing-gaps-chris-d-avella-md</loc><video:video><video:publication_date>2026-04-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d276e2f004a1391c5eafec3cf863348b82c21428-1267x706.png</video:thumbnail_loc><video:title><![CDATA[Nurse Navigation, Reflex Testing Key to Closing Molecular Testing Gaps: Christopher D'Avella, MD]]></video:title><video:description><![CDATA[Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392872518112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/lung-cancer-molecular-testing-nears-70-still-falls-short-of-universal-use-christopher-d-avella-md</loc><video:video><video:publication_date>2026-04-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d276e2f004a1391c5eafec3cf863348b82c21428-1267x706.png</video:thumbnail_loc><video:title><![CDATA[Lung Cancer Molecular Testing Nears 70%, Still Falls Short of Universal Use: Christopher D'Avella, MD]]></video:title><video:description><![CDATA[Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392871341112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/provider-shortages-payment-gaps-drive-pediatric-access-inequities-chris-johnson</loc><video:video><video:publication_date>2026-04-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/186b5049a053c4b5a8ecc3e8da7e7d9a66266d1b-1472x808.png</video:thumbnail_loc><video:title><![CDATA[Provider Shortages, Payment Gaps Drive Pediatric Access Inequities: Chris Johnson, MBA]]></video:title><video:description><![CDATA[Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes create real barriers to care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392810893112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nancy-lewis-md-eyes-health-equity-global-reach-in-first-year-as-nccn-cso</loc><video:video><video:publication_date>2026-04-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2a3050c51ed1269b9f4be61198d193109bb966e5-1024x576.png</video:thumbnail_loc><video:title><![CDATA[Nancy Lewis, MD, Eyes Health Equity, Global Reach in First Year as NCCN CSO]]></video:title><video:description><![CDATA[Nancy L. Lewis, MD, MBS, FACP, discusses her path from the clinic to biopharma and her goals as NCCN's new CSO, including health equity and faster drug development.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392811978112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-term-bimekizumab-data-confirm-sustained-efficacy-consistent-safety-in-hidradenitis-suppurativa-steven-daveluy-md</loc><video:video><video:publication_date>2026-04-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/dceba95785a3efd43a93bffed87dd17a61c93c4f-2793x1526.png</video:thumbnail_loc><video:title><![CDATA[Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD]]></video:title><video:description><![CDATA[Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392769357112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/shawn-davis-md-on-how-payers-should-think-about-obesity-treatment-return-on-investment</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/874fce1d80d5a7f0aa6c50f9e3dcee1701d3b017-2934x1624.png</video:thumbnail_loc><video:title><![CDATA[Shawn Davis, MD, on How Payers Should Think About Obesity Treatment Return on Investment ]]></video:title><video:description><![CDATA[With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392687176112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/teclistamab-plus-daratumumab-approval-marks-milestone-in-myeloma-care-ajai-chari-md</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/eac625fbd895397e712a89c148ed2fd9ec517802-1920x1080.jpg</video:thumbnail_loc><video:title><![CDATA[Teclistamab Plus Daratumumab Approval Marks Milestone in Myeloma Care: Ajai Chari, MD]]></video:title><video:description><![CDATA[Ajai Chari, MD, discusses the teclistamab-daratumumab approval, highlighting durable remissions, infection management, and the need for community oncologist uptake.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392518599112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/geographic-variation-in-psoriasis-care-epidemiology-access-and-prescribing-behavior</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[Geographic Variation in Psoriasis Care: Epidemiology, Access, and Prescribing Behavior]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, examines how geographic variation in psoriasis patient characteristics and biologic prescribing reflects a complex interplay of insurance access, formulary structure, practice site demographics, and regional socioeconomic factors.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392167749112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/initiating-biologic-therapy-why-il-23-inhibitors-are-leading-the-way</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[Initiating Biologic Therapy: Why IL-23 Inhibitors Are Leading the Way]]></video:title><video:description><![CDATA[Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient counseling, and versatility in managing psoriatic comorbidities.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392167445112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-96-week-data-reveal-about-dor-isl-in-diverse-patient-populations</loc><video:video><video:publication_date>2026-04-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[What 96-Week Data Reveal About DOR/ISL in Diverse Patient Populations]]></video:title><video:description><![CDATA[Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392179615112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/global-cohort-data-bolster-confidence-in-dolutegravir-for-pediatric-hiv-care</loc><video:video><video:publication_date>2026-04-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/014946710d58e8f857d1740ee1a8facd3c5ba97d-1275x713.png</video:thumbnail_loc><video:title><![CDATA[Global Cohort Data Bolster Confidence in Dolutegravir for Pediatric HIV Care]]></video:title><video:description><![CDATA[Global pediatric HIV data show dolutegravir links to early modest weight gain that plateaus by year 2, easing concerns and highlighting regional nutrition gaps.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391202886112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/vitamin-d-shows-potential-to-reduce-long-covid-symptoms-joann-e-manson-md-mph-drph</loc><video:video><video:publication_date>2026-04-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d4b6b3bafba646d3ff906d6459d1cb6e286189c8-660x370.png</video:thumbnail_loc><video:title><![CDATA[Vitamin D Shows Potential to Reduce Long COVID Symptoms: JoAnn E. Manson, MD, MPH, DrPH]]></video:title><video:description><![CDATA[A study suggests vitamin D may reduce long COVID symptoms at 8 weeks, although larger trials are needed to confirm benefits and optimal timing, explains JoAnn E. Manson, MD, MPH, DrPH.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392641471112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/balancing-efficacy-and-tolerability-in-skin-cancer-treatment-todd-schlesinger-md</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ed361303a971fd5c899bfe5d91143c5b14c209df-2791x1529.png</video:thumbnail_loc><video:title><![CDATA[Balancing Efficacy and Tolerability in Skin Cancer Treatment: Todd Schlesinger, MD]]></video:title><video:description><![CDATA[Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392519765112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/beyond-bmi-shawn-davis-md-on-why-adiposity-is-the-better-measure-for-managing-obesity</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/874fce1d80d5a7f0aa6c50f9e3dcee1701d3b017-2934x1624.png</video:thumbnail_loc><video:title><![CDATA[Beyond BMI: Shawn Davis, MD, on Why Adiposity Is the Better Measure for Managing Obesity]]></video:title><video:description><![CDATA[Shawn Davis, MD, explains why shifting from BMI to adiposity-based care could transform how health systems allocate resources and reduce obesity-driven hospital costs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392155060112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/molecular-end-points-poised-to-transform-myeloma-drug-approval-nicholas-richardson-do-mph</loc><video:video><video:publication_date>2026-04-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fcbd08165e590bd5c7b823b0594bb588fa91d1c-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Molecular End Points Poised to Transform Myeloma Drug Approval: Nicholas Richardson, DO, MPH]]></video:title><video:description><![CDATA[The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies, says Nick Richardson, DO, MPH.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391539882112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/top-reasons-dermatologists-value-the-aad-2026-annual-meeting</loc><video:video><video:publication_date>2026-04-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e738f76a11ec0caaddc25ee869991006b495af34-1200x720.png</video:thumbnail_loc><video:title><![CDATA[Top Reasons Dermatologists Value the AAD 2026 Annual Meeting]]></video:title><video:description><![CDATA[Key session speakers and abstract presenters share their highlights of attending AAD 2026. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392457528112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/understanding-zbmi-trajectories-before-and-after-dolutegravir-initiation</loc><video:video><video:publication_date>2026-04-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/014946710d58e8f857d1740ee1a8facd3c5ba97d-1275x713.png</video:thumbnail_loc><video:title><![CDATA[Understanding zBMI Trajectories Before and After Dolutegravir Initiation]]></video:title><video:description><![CDATA[A global cohort has tracked pediatric HIV growth after dolutegravir, showing early catch-up weight gain, then stable BMI without long-term obesity risk.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391202990112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/avapritinib-data-show-durable-benefits-including-qol-in-indolent-systemic-mastocytosis-lauren-madigan-md</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/81812d93f2761d1f960e576c467ad95ab1408730-2839x1551.png</video:thumbnail_loc><video:title><![CDATA[Avapritinib Data Show Durable Benefits Including QOL in Indolent Systemic Mastocytosis: Lauren Madigan, MD]]></video:title><video:description><![CDATA[Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients with indolent systemic mastocytosis.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392154521112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rethinking-risk-active-surveillance-and-biomarker-driven-care</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Rethinking Risk: Active Surveillance and Biomarker-Driven Care]]></video:title><video:description><![CDATA[Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP inhibitor eligibility now requires genetic testing at the hormone-sensitive stage.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392159972112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nonsteroidal-topicals-in-psoriasis-from-reactive-to-proactive-management</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[Nonsteroidal Topicals in Psoriasis: From Reactive to Proactive Management]]></video:title><video:description><![CDATA[Nonsteroidal topicals like roflumilast are enabling proactive, long-term psoriasis control across a broad range of patients, reducing reliance on corticosteroids and minimizing the need for systemic escalation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392168141112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-dor-isl-noninferiority-means-for-first-line-hiv-care</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2145d00c47be064dd047d335bcbaf96078efda2f-776x438.png</video:thumbnail_loc><video:title><![CDATA[What DOR/ISL Noninferiority Means for First-Line HIV Care]]></video:title><video:description><![CDATA[Phase 3 data show DOR/ISL matches standard INSTI-based therapy in efficacy and safety, signaling a potential shift in first-line HIV treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392178349112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-role-of-real-world-evidence-in-psoriasis-treatment-decisions</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d072e08706bc01a25795bad18219ae4adb16becc-778x438.png</video:thumbnail_loc><video:title><![CDATA[The Role of Real-World Evidence in Psoriasis Treatment Decisions]]></video:title><video:description><![CDATA[Real-world evidence complements clinical trial data by capturing how psoriasis therapies perform across diverse patient populations and treatment contexts in everyday practice.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392166776112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/translating-guideline-updates-to-clinical-practice-what-s-new-and-why-it-matters</loc><video:video><video:publication_date>2026-03-31</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1f12cc94ed715aa6360bc6e5669713eee7a1506b-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Translating Guideline Updates to Clinical Practice: What's New and Why It Matters]]></video:title><video:description><![CDATA[New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for taxane-naive mCRPC and PARP inhibitors in the hormone-sensitive setting.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392159972112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/once-daily-oral-zasocitinib-delivers-rapid-durable-skin-clearance-for-psoriasis-melinda-gooderham-md-msc-frcpc</loc><video:video><video:publication_date>2026-03-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2f49a9dc243caaf5cea0b7b81d607b9ccc6af1ae-2806x1579.png</video:thumbnail_loc><video:title><![CDATA[Once-Daily Oral Zasocitinib Delivers Rapid, Durable Skin Clearance for Psoriasis: Melinda Gooderham, MD, MSc, FRCPC]]></video:title><video:description><![CDATA[Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392093714112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/new-immunotherapy-advances-and-multidisciplinary-care-strategies-for-advanced-skin-cancer-todd-schlesinger-md</loc><video:video><video:publication_date>2026-03-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/1d7343f005a15435825003e89ee8ba940f8f20a7-2791x1529.png</video:thumbnail_loc><video:title><![CDATA[New Immunotherapy Advances and Multidisciplinary Care Strategies for Advanced Skin Cancer: Todd Schlesinger, MD]]></video:title><video:description><![CDATA[Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392067254112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/oral-jak1-inhibitor-povorcitinib-shows-durable-54-week-efficacy-favorable-safety-in-hs-martina-porter-md</loc><video:video><video:publication_date>2026-03-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/589cdca915cf617cb82f323879d96df7d632ca2e-2829x1546.png</video:thumbnail_loc><video:title><![CDATA[Oral JAK1 Inhibitor Povorcitinib Shows Durable 54-Week Efficacy, Favorable Safety in HS: Martina Porter, MD]]></video:title><video:description><![CDATA[Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392060474112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/tralokinumab-shows-strong-real-world-efficacy-in-atopic-dermatitis-for-patients-with-skin-of-color-april-armstrong-md-mph</loc><video:video><video:publication_date>2026-03-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b81a48122bc9f1ca4df834b64dcdb658b616a2b7-2828x1590.png</video:thumbnail_loc><video:title><![CDATA[Tralokinumab Shows Strong Real-World Efficacy in Atopic Dermatitis for Patients With Skin of Color: April Armstrong, MD, MPH]]></video:title><video:description><![CDATA[April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6392050802112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/icotrokinra-delivers-complete-skin-clearance-through-week-52-with-strong-safety-profile-linda-stein-gold-md</loc><video:video><video:publication_date>2026-03-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/547c550bca0b907b92787066b8174486b916f3e1-2823x1610.png</video:thumbnail_loc><video:title><![CDATA[Icotrokinra Delivers Complete Skin Clearance Through Week 52 With Strong Safety Profile: Linda Stein Gold, MD]]></video:title><video:description><![CDATA[Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391953235112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/recognizing-morphologic-differences-diagnostic-challenges-in-asian-patients-joseph-lam-md</loc><video:video><video:publication_date>2026-03-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/5c2ba442ba6adfdced7e60cfc225e385e1e0a062-2835x1595.png</video:thumbnail_loc><video:title><![CDATA[Recognizing Morphologic Differences, Diagnostic Challenges in Asian Patients: Joseph Lam, MD]]></video:title><video:description><![CDATA[Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391969353112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/improving-remote-dermatology-care-diagnosis-and-clinical-trial-diversity-james-song-md</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c1ffee0a37a76ddc8afe18b6a6f243047cddd233-2660x1323.png</video:thumbnail_loc><video:title><![CDATA[Improving Remote Dermatology Care, Diagnosis, and Clinical Trial Diversity: James Song, MD]]></video:title><video:description><![CDATA[James Song, MD, discusses the direction teledermatology is heading and how more inclusive clinical trials can improve outcomes for patients of color.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391086614112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/tapinarof-shows-early-sustained-gains-in-moderate-to-severe-atopic-dermatitis-linda-stein-gold-md</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/547c550bca0b907b92787066b8174486b916f3e1-2823x1610.png</video:thumbnail_loc><video:title><![CDATA[Tapinarof Shows Early, Sustained Gains in Moderate to Severe Atopic Dermatitis: Linda Stein Gold, MD]]></video:title><video:description><![CDATA[Linda Stein Gold, MD, shares recent findings from the pooled phase 3 analysis of the ADORING 1 and ADORING 2 trials for atopic dermatitis. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391858742112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/guideline-updates-refine-risk-stratification-and-diagnosis-in-cscc</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Guideline Updates Refine Risk Stratification and Diagnosis in CSCC]]></video:title><video:description><![CDATA[Updated guidelines for CSCC introduce more granular risk stratification and emphasize deeper biopsies to improve staging accuracy and guide decisions about surgery and systemic therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391139095112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/the-expanding-role-of-checkpoint-inhibitors-in-cscc-management</loc><video:video><video:publication_date>2026-03-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/88a8eef0d85d435b85b5ed0c5f92696000288dc8-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[The Expanding Role of Checkpoint Inhibitors in CSCC Management]]></video:title><video:description><![CDATA[NCCN guideline updates for CSCC emphasize immunotherapy as a cornerstone across disease stages, expanding its role from advanced disease into neoadjuvant and adjuvant settings.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391140547112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/optimizing-access-and-closing-data-gaps-in-attr-cm-management</loc><video:video><video:publication_date>2026-03-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Optimizing Access and Closing Data Gaps in ATTR-CM Management]]></video:title><video:description><![CDATA[How payers curb inappropriate ATTR-CM therapy use with better scans, prior auth, real-world outcomes, and telemedicine to speed access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390318677112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/navigating-benefit-design-and-utilization-management-in-attr-cm</loc><video:video><video:publication_date>2026-03-26</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Navigating Benefit Design and Utilization Management in ATTR-CM]]></video:title><video:description><![CDATA[Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390321615112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-price-transparency-may-affect-health-care-costs-john-barkett-mba</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d8dd1323e8cb671af7f493a4d9b25ba7ddcefc5c-2614x1263.png</video:thumbnail_loc><video:title><![CDATA[How Price Transparency May Affect Health Care Costs: John Barkett, MBA]]></video:title><video:description><![CDATA[John Barkett, MBA, discusses how health care price transparency can affect both patient out-of-pocket costs and overall health care spending.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391651351112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/overcoming-barriers-and-future-integration-of-subcutaneous-therapies-in-lung-cancer</loc><video:video><video:publication_date>2026-03-25</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02778d15886126e1ff4e6386831e375422879153-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer]]></video:title><video:description><![CDATA[Subcutaneous cancer therapy cuts chair time and IV needs, but brings site reactions, volume limits, and policy hurdles clinics must solve.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6389526484112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/jak-inhibitors-show-promise-in-alopecia-but-long-term-management-requires-more-study-maria-hordinsky-md</loc><video:video><video:publication_date>2026-03-23</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/85b9d1499db4b92c856b5d84b30195913ce55650-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[JAK Inhibitors Show Promise in Alopecia, but Long-Term Management Requires More Study: Maria Hordinsky, MD]]></video:title><video:description><![CDATA[Maria Hordinsky, MD, discusses the promise of Janus kinase (JAK) inhibitors in treating alopecia areata in the long term.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391274102112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/noteworthy-studies-on-jak-inhibitors-skin-gut-relationship-in-alopecia-areata-maria-hordinsky-md</loc><video:video><video:publication_date>2026-03-21</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/85b9d1499db4b92c856b5d84b30195913ce55650-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Noteworthy Studies on JAK Inhibitors, Skin-Gut Relationship in Alopecia Areata: Maria Hordinsky, MD]]></video:title><video:description><![CDATA[Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical Dermatology Conference.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391264893112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/important-emerging-oral-therapies-guidelines-to-be-highlighted-at-aad-2026-james-song-md</loc><video:video><video:publication_date>2026-03-20</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c1ffee0a37a76ddc8afe18b6a6f243047cddd233-2660x1323.png</video:thumbnail_loc><video:title><![CDATA[Important Emerging Oral Therapies, Guidelines to Be Highlighted at AAD 2026: James Song, MD]]></video:title><video:description><![CDATA[James Song, MD, previews new oral therapies and guidelines psoriasis, atopic dermatitis, and chronic spontaneous urticaria. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391080155112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sub-q-mosunetuzumab-improves-clinic-workflow-patient-experience-zahra-mahmoudjafari-pharmd-mba-bcop</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/366007567c2ffa2d40cdc0a8740facd096ad8973-2880x1622.png</video:thumbnail_loc><video:title><![CDATA[Sub-Q Mosunetuzumab Improves Clinic Workflow, Patient Experience: Zahra Mahmoudjafari, PharmD, MBA, BCOP]]></video:title><video:description><![CDATA[The newly approved mosunetuzumab for relapsed/refractory follicular lymphoma improves clinic efficiency and patient experience, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391087016112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/applying-value-based-frameworks-in-attr-cm-management</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Applying Value-Based Frameworks in ATTR-CM Management]]></video:title><video:description><![CDATA[Real-world evidence and claims data compare amyloidosis therapies, linking outcomes and symptom burden to total cost of care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390320053112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/assessing-clinical-and-economic-factors-in-treatment-selection-and-payer-decision-making</loc><video:video><video:publication_date>2026-03-19</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making]]></video:title><video:description><![CDATA[In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists explore the key clinical and economic considerations that drive therapy selection across the three available ATTR-CM treatments. Dr. Alexander opens by emphasizing shared decision-making as a foundational principle, noting that in the absence of head-to-head data, patient preferences carry significant weight alongside clinical judgment. He outlines several practical factors influencing treatment choice, including route of administration, as vutrisiran is a quarterly injection given in a healthcare setting, acoramidis is a twice-daily oral pill, and tafamidis is a once-daily oral pill, each presenting distinct advantages depending on patient circumstances such as pill burden or transportation access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390320246112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-covid-immune-response-and-why-covid-19-vaccination-still-matters-noah-greenspan-dpt</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/560528fda7ae6aa2a1e3b7ab4beb8e687f377236-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Long COVID, Immune Response, and Why COVID-19 Vaccination Still Matters: Noah Greenspan, DPT]]></video:title><video:description><![CDATA[Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce infection risk and severity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390870370112 </video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/optimizing-subcutaneous-therapies-in-nsclc-practical-integration-patient-selection-and-workflow-considerations</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02778d15886126e1ff4e6386831e375422879153-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow Considerations]]></video:title><video:description><![CDATA[Subcutaneous cancer therapy trims chair time and costs, but volume limits and reactions matter—learn how clinics streamline workflows.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6389526685112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/personalized-selection-of-immunotherapy-strategies-in-metastatic-nsclc-and-future-evidence-gaps</loc><video:video><video:publication_date>2026-03-18</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02778d15886126e1ff4e6386831e375422879153-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps]]></video:title><video:description><![CDATA[Experts decode NSCLC PD‑L1 trials, when immunotherapy alone works, why crossover matters, and who still benefits from adding chemotherapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6389527080112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/sub-q-mosunetuzumab-approval-simplifies-r-r-follicular-lymphoma-care-zahra-mahmoudjafari-pharmd-mba-bcop</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/366007567c2ffa2d40cdc0a8740facd096ad8973-2880x1622.png</video:thumbnail_loc><video:title><![CDATA[Sub-Q Mosunetuzumab Approval Simplifies R/R Follicular Lymphoma Care: Zahra Mahmoudjafari, PharmD, MBA, BCOP]]></video:title><video:description><![CDATA[Subcutaneous mosunetuzumab simplifies the delivery of the bispecific therapy for patients with relapsed/refractory follicular lymphoma, says Zahra Mahmoudjafari, PharmD, MBA, BCOP.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6391038556112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/why-safety-net-hospitals-are-leading-the-way-on-childhood-vaccine-uptake</loc><video:video><video:publication_date>2026-03-17</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b904964d9ddec0e008c7155916d1cb19c357066e-1122x626.png</video:thumbnail_loc><video:title><![CDATA[Why Safety-Net Hospitals Are Leading the Way on Childhood Vaccine Uptake]]></video:title><video:description><![CDATA[Vaccine schedule shifts may widen gaps; learn how safety-net workflows and community education counter misinformation and boost uptake.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390873519112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unprecedented-efficacy-in-the-majestec-3-trial-in-multiple-myeloma-ajay-k-nooka-md-mph</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a926661cf4d2e312bf314be11f52e147665b8c1b-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Unprecedented Efficacy in the MajesTEC-3 Trial in Multiple Myeloma: Ajay K. Nooka, MD, MPH]]></video:title><video:description><![CDATA[Beyond progression-free survival, the combination of teclistamab and daratumumab hyaluronidase-fihj showed deep clinical responses, notes Ajay K. Nooka, MD, MPH. ]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390885604112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/managing-long-covid-oxygen-therapy-and-autonomic-reset-noah-greenspan-dpt</loc><video:video><video:publication_date>2026-03-13</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/560528fda7ae6aa2a1e3b7ab4beb8e687f377236-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Oxygen Therapy and Autonomic Reset to Manage Long COVID: Noah Greenspan, DPT]]></video:title><video:description><![CDATA[Noah Greenspan, DPT, discusses how oxygen therapy, detailed evaluation, and trial-and-error approaches may help manage long COVID symptoms.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390867812112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/potential-budget-decisions-in-florida-could-significantly-affect-hiv-care-lindsey-dawson-ma</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/70a7775d264ccf4059a94711edfed5d2051a99c8-1280x720.jpg</video:thumbnail_loc><video:title><![CDATA[Potential Budget Decisions in Florida Could Significantly Affect HIV Care: Lindsey Dawson, MA]]></video:title><video:description><![CDATA[Lindsey Dawson, MA, speaks about how budget decisions regarding ADAPs in Florida could affect patients with HIV should these decisions be made permanent.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390742759112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/holding-the-line-peter-staley-on-resistance-prep-access-and-the-fight-to-preserve-hiv-progress</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/463d16b235449a954f87c7350d640c04681f9ce3-1200x672.png</video:thumbnail_loc><video:title><![CDATA[Holding the Line: Peter Staley on Resistance, PrEP Access, and the Fight to Preserve HIV Progress]]></video:title><video:description><![CDATA[Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390735370112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/key-efficacy-and-safety-considerations-for-payers-in-attr-cm</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Key Efficacy and Safety Considerations for Payers in ATTR-CM]]></video:title><video:description><![CDATA[Long-term ATTR-CM trial data show durable benefits with early tafamidis or acoramidis, fewer deaths/hospitalizations, and manageable safety.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390321521112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/evaluating-transthyretin-stabilizers-and-silencers-in-attr-cm</loc><video:video><video:publication_date>2026-03-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4c9e02c70458990c2c1bece75cae57e4c9b3ec36-2346x1312.png</video:thumbnail_loc><video:title><![CDATA[Evaluating Transthyretin Stabilizers and Silencers in ATTR-CM]]></video:title><video:description><![CDATA[Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390320245112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/access-resistance-and-the-road-ahead-in-sti-prevention-jeanne-m-marrazzo-md-mph</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b03a8642fe33915720721fad9116998cacc9bc01-1200x675.png</video:thumbnail_loc><video:title><![CDATA[Access, Resistance, and the Road Ahead in STI Prevention: Jeanne M. Marrazzo, MD, MPH]]></video:title><video:description><![CDATA[null]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390699387112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/key-immunotherapy-and-chemoimmunotherapy-trials-shaping-metastatic-nsclc-management</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02778d15886126e1ff4e6386831e375422879153-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Key Immunotherapy and Chemoimmunotherapy Trials Shaping Metastatic NSCLC Management]]></video:title><video:description><![CDATA[Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6389527268112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/dual-immunotherapy-strategies-in-metastatic-nsclc-evidence-safety-and-clinical-decision-making</loc><video:video><video:publication_date>2026-03-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02778d15886126e1ff4e6386831e375422879153-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Dual Immunotherapy Strategies in Metastatic NSCLC: Evidence, Safety, and Clinical Decision-Making]]></video:title><video:description><![CDATA[Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6389526113112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/optimizing-bcma-directed-sequencing-in-multiple-myeloma-therapy-ajai-chari-md</loc><video:video><video:publication_date>2026-03-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a765e408d9c31f47fee9e979668d8012a7936e98-1200x675.jpg</video:thumbnail_loc><video:title><![CDATA[Optimizing BCMA-Directed Sequencing in Multiple Myeloma Therapy: Ajai Chari, MD]]></video:title><video:description><![CDATA[Ajai Chari, MD, discusses how the results of the MajesTEC-3 trial may translate to a real-world second-line population with multiple myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390679035112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/diagnosing-and-managing-long-covid-symptoms-in-practice-noah-greenspan-dpt</loc><video:video><video:publication_date>2026-03-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/560528fda7ae6aa2a1e3b7ab4beb8e687f377236-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Diagnosing and Managing Long COVID Symptoms in Practice: Noah Greenspan, DPT]]></video:title><video:description><![CDATA[Noah Greenspan, DPT explains challenges diagnosing long COVID and strategies like pacing, compression, and electrolytes to support recovery.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6390641242112</video:player_loc></video:video></url></urlset>